Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

Antonio Palumbo, Asher Chanan‐Khan, Katja Weisel et al. · New England Journal of Medicine · 2016 · 1.5K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

Meletios Α. Dimopoulos, Philippe Moreau, Antonio Palumbo et al. · The Lancet Oncology · 2015 · 849 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

Ajai Chari, Dan T. Vogl, Maria Gavriatopoulou et al. · New England Journal of Medicine · 2019 · 673 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy

Ujjawal H. Gandhi, Robert F. Cornell, Arjun Lakshman et al. · Leukemia · 2019 · 616 citations

Medicine, Hematology, Oncology +13

Efficacy and safety of once-weekly bortezomib in multiple myeloma patients

Alessandra Larocca, Davide Rossi, Maide Cavalli et al. · Blood · 2010 · 382 citations · Full text

Medicine, Hematology, Pharmacology +14